Response evaluation in HER2-positive mucinous breast carcinoma after neoadjuvant chemotherapy: Progressive disease clinically but complete response pathologically

Asian J Surg. 2022 Nov;45(11):2405-2406. doi: 10.1016/j.asjsur.2022.05.069. Epub 2022 May 25.

Authors

Bingjian Xue¹, Xinxing Wang¹, Yujie Zhang¹, Xinhong Pei²

Affiliations

¹ Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
² Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address: 1007542778@qq.com.

PMID: 35643896
DOI: 10.1016/j.asjsur.2022.05.069

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Breast Neoplasms* / surgery
Chemotherapy, Adjuvant
Female
Humans
Neoadjuvant Therapy*
Receptor, ErbB-2
Remission Induction
Treatment Outcome

Substances

Receptor, ErbB-2